Close Menu

NEW YORK – Cancer patients with certain BRAF mutations might be more likely to respond to anti-EGFR therapy, potentially allowing clinicians to more precisely target their tumors.

Scientists have recently grouped BRAF mutations into three classes, each of which may be susceptible to different treatment approaches, though researchers are still investigating.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.